The more assumptions you have to make, the more unlikely an explanation is.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ok, I fail to see an answer to my question and I don’t see a problem with licensing a tech. Until you pursue answers from the company about the info you are looking for, there is no point in discussing it.
or anything “furture” in US dollars SK has an 11.5BB MC very large company prepared for growth.
perhaps they are extremely busy. for me if this had happened last thursday or friday i would not have been able to give it any attention.
pre market sales in otc look like mm’s looking around for stray shares. leftovers from previous day or such.
short position was 2mm as of 3/15.
The experience of the CFO gives me a lot of confidence on the finance side.
Everything about the BOD and CEO screams experience. There is such a thing as paying for the use of a patent or trademark if they are needed. Why at this stage or maybe at all would they need worldwide reach?
Well both records are "objected" of the "2 records found". If Medigrity had responded to the objected report, which they would have to do in order to receive a Trademark, the response would be in the record.
Their DocLynk sounds like a private chat app for doctor's, dentist and students to interact on:
"DocLynk is a state-of-the-art internet based free, safe and secured professional networking platform that helps the medical practitioners (Doctors and Dentists) and medical students to connect, collaborate and share knowledge."
I just don't get why that particular group would need such an app.
I.e. my BS detector is flashing red.
SK hynix completes construction of new chip plant in S. Korea
SEOUL, Feb. 1 (Yonhap) — SK hynix Inc., South Korea’s No. 2 chipmaker, said Monday it has completed the construction of a new chip production line in the country as the company tries to expand its presence in the memory sector.
https://capitalconnect.kr/2021/02/01/sk-hynix-completes-construction-of-new-chip-plant-in-s-k
link from another board
So Sk and Netlist jumped first and locked in a partnership and royalty for Netlist. Kissin' Cousins....
NETLIST AND SK HYNIX ENTER INTO STRATEGIC AGREEMENTS FOR PATENTS, TECHNOLOGY AND PRODUCT SUPPLY
C.K. Hong, Netlist's Chief Executive Officer said, "We are delighted with the recognition of the value of Netlist's intellectual property and very much look forward to partnering with SK hynix, a global leader in memory and storage technology."
The agreements provide SK hynix with access to Netlist's portfolio of U.S. and foreign patents. Netlist will receive a royalty from SK hynix, a cross license to SK hynix's patent portfolio and supply of SK hynix's memory and storage products. The companies also plan to collaborate on Netlist's HD CXL technology for future commercialization.
Netlist and SK hynix have agreed to end all pending matters in the U.S. District Court for the Western District of Texas and the Patent Trial and Appeals Board of the U.S. Patent and Trademark Office.
Netlist will host a conference call to discuss today's announcement at 5:00 p.m. Eastern Time on April 7, 2021. Netlist encourages participants to pre-register for the conference call. Callers who pre-register will be given a unique PIN to gain immediate access to the call and bypass the live operator. To pre-register, click here.
For those who would like to join the call but have not pre-registered, they can do so by dialing +1 (412) 317-5443 and requesting the "Netlist Conference Call."
By "they" I'm thinking you are referring to the company in India? Have you confirmed they are not in business and therefore their DocLynk app would not be operating? Just curious....
Yes, and a very different animal compared to HLYK's DocLynk for telemedicine.
This is my 1st up close look at an infringement suit. Biotech taught me patience and market chats taught me who to block . Also, so far the judges for N V G and N V Sk are supporting "moving thing forward" methods.
That's as good as an FDA approval or at least an acceptance of an NDA/BLA.
Nobody can know the future, but my confidence in good news this year is high.
con gusto
LaSniper
Same guy says his formula has potential to bring $15 pps, which he doesn't go into. I'm not surprised folks have wildly different estimates. One is applying some stock valuation techniques to another case QUALCOMM vs Apple
The 5% guy is taking the "letter of the law" on ****"lost sales for 5% of servers" then applying a multiple to pps (a stock valuation technique).
****"lost sales for 5% of servers"--where did he get that? I don't think that # has been determined yet.
Either result I'm thrilled! Netlist has a good case.
Unambiguous comes to mind. "and with a lot of chances to win"
That is an quite the article. It is amazing that NLST got through the bloody gauntlet of proving their patents.
Could the pricing on Gen4 be part of the settlement? That's what I would want to know, especially having (personally) no idea what the $ value is.
Sometimes I get the feeling there is a bunch of ego involved in g's (seemingly) cavalier attitude regarding another's property.
Makes my heart sing! “With availability in 8TB and 16TB, and a robust feature set, Netlist's N1962 SSDs provide the high performance and supply requirements demanded by enterprise customers.”
Timely pr from NLST. They are plugging away building the business. And after reading Barron’s report I’m more convinced the risk/reward for NLST is a good one.
NETLIST ANNOUNCES PRODUCT AVAILABILITY AND SHIPMENT OF ENTERPRISE GEN4 NVME(TM) SOLID STATE DRIVES
https://investors.netlist.com/websites/netlist/English/2120/us-press-release.html?airportNewsID=93ba83c7-cfde-4768-89f5-032544a0c353
And practically speaking what mega firms like GS and JPM do about exposure to blue chip short positions has little to do with volatility in an OTC stock which had a .33ish% short position as of 2 weeks ago, except perhaps the fud category.
The above is further enforced by recent events with INPHI. Even a $300MM cash settlement would go a long way to bolstering confidence in additional settlements not to mention NLST balance sheet. Which, as is clear, is improving through sales even w/o pending court actions.
So the point about this guy making an exception for AMC is quite relevant considering the 11% short ratio and the popularity of the stock. AMC is potentially much more entangled with the current hedge fund drama that NLST.
So here is another voice about the current hedge fund drama:
Investing Lessons From the Archegos Saga -- Barrons.com
3/30/21, 5:11 AM
As the Archegos margin call saga continues to develop, lessons are coming into focus. None of them are new, but it's worth reviewing them.
The first: Leverage kills. Archegos was reported to have about $10 billion under management and anywhere from three to 10 times that amount in market exposure. That's risky. If someone with $10 billion invests all of it and loses 20%, said investor still has $8 billion left over. If another person with $10 billion invests $50 billion and loses 20%, that investor has nothing left because 20% of $50 is $10 billion.
The second: Excessive concentration is bad. Archegos was reported to have most of its market exposure concentrated in a few positions such as ViacomCBS. That raises risk. There are investors that advocate some concentration, such as Warren Buffett. But Berkshire Hathaway's largest stockholding, Apple, accounts for about 25% of its equity portfolio and 13% of its total market cap. And that stock is, after all, Apple. It accounts for almost 6% of the entire S&P 500.
The third lesson: Be diligent. Goldman Sachs told Barron's in an emailed statement on Monday morning that their losses stemming from Archegos were immaterial. Goldman watched carefully and acted fast when something was off. That combination, in the market, is almost as good as being right.
Of course, people can trade stocks the same way Archegos did. But that isn't investing. That's more akin to trading. And the biggest lesson is knowing the difference between the two.
-- Al Root
That guy took 20% off his long term blue chip portfolio. He is still pumping AMC. Why not tell that part of story?
700k short as someone else mentioned is not difficult for a 2.4MM share avg per day situation.
I'd rather see trading dry up till the uncertainty (couple weeks or less) passes than see newbies sell then wish they hadn't.
Another from Wesley:
Here is all you need to know about intervening rights in the Google or Inphi case.
The doctrine of intervening rights serves, under certain circumstances, to protect an accused infringer’s right to continue using, selling, and offering to sell specific products that are covered by reissued or reexamined claims. Particularly, the accused infringer may be entitled to such intervening rights when the scope of the claims at issue have “substantially changed”
Netlist's additional & amended claims all are related to rank multiplication & the 40 new claims are the same claims worded in another manner to clarify while the original 38 valid claims in the reexamination of the patent are the same claims added to each other in larger claims so they have the same scope so there is no basis for intervening rights.
The statutory basis for absolute intervening rights can be found in 35 U.S.C. § 252, 2nd paragraph, which states: A reissued patent shall not abridge or affect the right of any person…who, prior to the grant of a reissue, …made…anything patented by the reissued patent, to continue the use of, to offer to sell, or to sell to others…the specific thing so made…unless [it] infringes a valid claim of the reissue patent which was in the original patent…, & Well 38 of the original claims of the 51 survived, surely there are a lot of original infringed claims in there in the reexamination of '912.
The reexaminated '912's first 6 large claims consist of a basic original claim with 5 or 6 original claims added, they are in total 38 original claims even using new paragraph for this matter.
Mar. 23, 2021-- Omeros Corporation (Nasdaq: OMER) and Quantum Leap Healthcare Collaborative announced that dosing of patients with narsoplimab in the I-SPY COVID-19 Trial began earlier this month. The I-SPY COVID-19 Trial is an adaptive platform trial sponsored by Quantum Leap Healthcare Collaborative. The goal of the trial is to screen rapidly, in parallel, multiple promising agents in order to identify drugs that will have a high impact on reducing mortality and avoid or reduce the duration of mechanical ventilation for critically ill COVID-19 patients.
“We’re excited that narsoplimab is one of the agents that has entered the I-SPY COVID-19 Trial,” said Laura Esserman, MD, MBA, co-founder of Quantum Leap Healthcare Collaborative, Principal Investigator of the I-SPY trial program, and Professor of Surgery and Radiology at the University of California – San Francisco. “The mechanism of action, specifically targeting endothelial injury, along with its safety profile and initial data generated in critically ill COVID-19 patients make a compelling case for this agent. The pulmonary and critical care investigators leading the I-SPY COVID Trial uniformly endorsed narsoplimab and made it a high-priority candidate for the trial. Together, we will be able to generate data on the ability of the agent to reduce the time to recovery and lower mortality.”
Narsoplimab is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of complement. It is the only complement inhibitor invited to participate in the I-SPY COVID-19 Trial. Narsoplimab has been administered under compassionate use to treat severely ill COVID-19 patients requiring mechanical ventilation, with impressive outcomes.
Continued
investor.omeros.com
Looks like the district judges decisions agree with you! Well said!
Nice post!!! Bullish!
Agree, that’s why short interest settlement date is important. Shorts must cover if under water. New rule means no wiggle room anymore. At least that’s how I understand it.
“settlement date is Monday 3/15” I’m referring to short settlements. Thought to qualify as the term settlement is getting thrown around a bit.
Of the several reports I’ve read this is by far the most credible ( to my ears) Thanks for the re-post Daylas.
settlement date is Monday 3/15
Sk will bank-roll all things Netlist and then some. That is huge, should be a giddy-up for G.
Well that sounds very good!
Yeah, if I'm bullish I buy when I can, so today I bought, based on the case in Texas.I used to live and breath pps, which is still a good idea, but Ii also have a life, .50 if not going to prevent me from buying.
Yes lots of wheels turning at any point something could bust open. The Sk hynix case will have news next week regarding Albrights comments on the Markmans hearing. That should be very interesting. I bought back some of my traders today.
That IS good news "judges actually leaned more towards Netlist with their schedule"
No surprises there, nobody thought G would collapse into acquiescence. The question for me was the judge, did Netlist get the referral to an intermediary? (#2)
Well it must mean Sk will need more from Netlist.
I’m not going to be able to listen. Hopefully
the judge will express a view point that gives a clue to how she see’s things going.
Oh I see, my understanding is the case management conference is a pre-Markman event. But perhaps in this judges court things are different. 15 minutes seems a bit short for a Markman though.